HER2-Negative Breast Carcinoma Clinical Trials
2 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377
Recruiting
Phase 2
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic40 enrolled1 locationNCT06450873
Recruiting
Not Applicable
Mobile Health for Adherence in Breast Cancer Patients
Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8+1 more
ECOG-ACRIN Cancer Research Group410 enrolled400 locationsNCT06112613
Recruiting
Not Applicable
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center40 enrolled2 locationsNCT05677802
Recruiting
Not Applicable
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
Emory University150 enrolled4 locationsNCT06534125
Recruiting
Phase 2
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
City of Hope Medical Center174 enrolled2 locationsNCT06042569
Recruiting
Phase 1Phase 2
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
Margaret Gatti-Mays42 enrolled1 locationNCT06026657
Recruiting
Early Phase 1
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Emory University40 enrolled4 locationsNCT05464810
Recruiting
Not Applicable
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Emory University30 enrolled4 locationsNCT05488145